Trial reportThe Journal of infectious diseases2025
Vector-Induced Humoral Responses After rVSVΔG-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies.
Trial report in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and Qualification of a VSV-N IgG ELISA to Assess Vector-Directed Humoral Immunity in VSV-Vectored Vaccine Studies.Vaccines · 2026Article
- Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance.Emerging infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundWhile vaccine antigen-induced antibodies are often used as proxies for vaccine efficacy, immune responses to vaccine vectors are less well-defined. We describe the kinetics of immunoglobulin (IgG) responses against the vector (vesicular stomatitis Indiana virus [VSIV]) nucleoprotein (N) and the inserted antigen (Ebola virus [EBOV]) glycoprotein (GP1,2) components of the rVSV-ZEBOV vaccine and evaluate their use as biomarkers to confirm self-reported vaccination status.
methodsWe selected 212 participants randomized to rVSV-ZEBOV (n = 107) or placebo (n = 105). Levels of IgG antibodies to EBOV GP1,2 or VSIV N were measured using an enzyme-linked immunosorbent assay and a newly developed single-molecule array (Simoa) immunoassay, respectively.
resultsAnti-EBOV GP1,2 and anti-VSIV N IgG were first detected 10-14 days postvaccination, further increased at 28 days, and remained stable through 360 days. Antibody titers were significantly correlated (P < 0.001) at 28 days (r = 0.47), 180 days (r = 0.45), and 360 days (r = 0.59). At 28 days, the area under the receiver operating characteristic curve (AUC) discriminated vaccinated from unvaccinated patients with high accuracy (AUC = 0.965 for anti-VSIV N IgG; AUC = 0.945 for anti-EBOV GP1,2 IgG [P < 0.001]).
conclusionsWe report a reliable assay to measure vector-induced humoral responses after rVSV-ZEBOV vaccination and demonstrate the assay's utility to confirm vaccination status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.